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Cancer-testis (CT) antigens are a large family of genes that are selectively expressed in human testis germ cells,
overexpressed in a variety of tumors and predominantly located on the X chromosome. To date, all known CT
antigens are protein-coding genes. Here, we identify miR-888 as the first miRNA with features characteristic of a
CT antigen. In a panel of 21 normal human tissues, miR-888 expression was high in testes and minimal or absent
in all other examined tissues. In situ hybridization localized miR-888 expression specifically to the early stages of
sperm development within the testes. Using The Cancer Genome Atlas database, we discovered that miR-888 was
predominately expressed in endometrial tumors, with a significant association to high-grade tumors and increased
percent invasion. In a separate panel of endometrial tumor specimens, we validated overexpression of miR-888 by
real-time polymerase chain reaction. In addition, miR-888 expression was highest in endometrial carcinosarcoma,
a rare and aggressive type of endometrial tumor. Moreover, we identified the progesterone receptor (PR), a potent
endometrial tumor suppressor, as a direct target of miR-888. These data define miR-888 as the first miRNA CT
antigen and a potential mediator of an aggressive endometrial tumor phenotype through down-regulation of PR.
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Cancer-testis (CT) antigens are a class of genes that are predominately
expressed in the adult testes and are overexpressed in several types of
tumors [1]. Within the testes, CT antigen expression localizes to the
testicular germ cells termed the spermatogonia [1]. Because of their
restricted expression in spermatogonia and the presence of a
blood-testis barrier, expression of CT antigens in cancer often
induces a tumor-directed immune response [1]. Consequently, CT
antigens were historically identified through immunologic techniques
such as T-cell epitope cloning and serological expression analysis of
cDNA expression libraries [1]. More recently, CT antigens have been
identified through analysis of expressed sequence tags for genes
exclusively expressed in testes and cancer [1]. These strategies have led
to the classification of more than 200 CT antigens (CT antigen
database, http://www.cta.lncc.br), with new CT antigens continuing
to be discovered [2]. Because their classification mainly relies on tissue
expression patterns, the function and immunogenic potential of the
majority of CT antigens remain unknown [3].One of the most intriguing features of CT antigens is their
predominant localization to the X chromosome. In fact, almost half of
all CT antigens are encoded by the X chromosome [1], and
Figure 1.MiR-888 is part of a multicopy gene family on the X chromosome. Using the University of California Santa Cruz Genome Browser
and the CT antigen database (http://www.cta.lncc.br), we generated a scaled diagram demonstrating the location of the major CT antigen
gene families on the X chromosome (bottom). Within the Xq27-X28 region (approximately 145,000,000 million bp to 155,000,000 million
bp), there are 38 classified CT antigens. The miR-888 gene (bold, underlined) is within this region at Xq27.3 and is part of a multicopy
miRNA gene family that also includes miR-890, miR-891a/b, and miR-892a/b (gray).
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are CT antigens [4] (Figure 1, bottom). These genes, termed CT-X
antigens, recently evolved in eutherian mammals through gene
translocation and duplication events to produce large multi-gene
families [1]. At least 38 classified CT-X antigens are clustered near the
end of the long arm of the X chromosome (Xq27-Xq28; Figure 1,
top). Whereas all currently established CT-X antigens are protein-
coding genes, this region also contains several reported miRNAs. In
particular, genomic duplication events resulted in the evolution of the
primate-specific miRNA gene family at Xq27.3 containing miR-888,
miR-890, miR-891a, miR-891b, miR-892a, and miR-892b
(Figure 1) [5]. The miR-888 gene family has restricted expression
in testes, and miR-888 has recently been reported to be overexpressed
in cancer [6,7]. However, the function of miR-888 in cancer has not
been sufficiently studied [8,9].
In an analysis of miRNA expression patterns in uterine endometrial
cancer (EC), we previously identified miR-888 as highly over-
expressed [7]. EC is the fourth most common cancer in women and
the most common gynecological malignancy [10]. While patient
outcomes have improved for most cancers over the past 10 years,
survival for EC patients has alarmingly decreased [10,11]. One of the
most potent tumor suppressors in the endometrium is the
progesterone receptor (PR), which activates gene expression to
induce differentiation, cell cycle arrest, and apoptosis [12–14]. In
addition, PR expression is often lost in advanced endometrial tumors
[15–17]. Therefore, characterization of the different mechanisms by
which PR expression is lost in EC can potentially improve our
understanding on how aggressive ECs develop.
Our objective in this study was to determine whether miR-888 is a
CT-X antigen and to understand its role in EC. MiR-888 is a
primate-specific miRNA that evolved through gene translocation and
duplication events on the X chromosome similar to other CT antigengenes. Here, we demonstrate that miR-888 expression is restricted to
the testes and localizes to cells in the early stages of spermatogenesis.
Using The Cancer Genome Atlas (TCGA) database, we found that
miR-888 was most highly expressed in endometrial tumors with a
significant association to high-grade tumors and increasing percent
invasion. In addition, we describe a novel mechanism of
PR inhibition in EC through miR-888. These data suggest that
miR-888 functions in endometrial tumors to inhibit PR-mediated
anti-proliferative signaling. We also suggest that miRNAs can
potentially be classified as CT antigens, with miR-888 as the
defining example.
Materials and Methods
Tissue Samples
Endometrial tissues were obtained under informed written consent
from patients undergoing hysterectomy at the University of Iowa
Hospitals and Clinics. The protocol was approved by the University
of Iowa Institutional Review Board (Protocol No. 200209010). A
total of 44 endometrial samples was collected, which included 9
samples of benign endometrium (BE), 18 endometrioid adenocarci-
nomas (EAs), 9 serous adenocarcinomas (SAs), and 8 carcinosarcomas
(CSs; Table S1). Rhesus macaque testis samples were generously
provided by Dr Jodi McBride of the Oregon National Primate
Research Center (Beaverton, OR). In this study, animals were killed
by sedation with ketamine followed by deep anesthesia with sodium
pentobarbital and then exsanguination as previously reported [18].
Samples were collected under a protocol that was reviewed and
approved by the Oregon Health & Science University Institutional
Animal Care and Use Committee (Protocol No. IS00002803, “RNA
interference therapy in a non-human primate model of Huntington's
disease”) as previously reported [18].
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Six EC cell lines (AN3CA, RL95-2, Hec1A, SK-UT-1B, ECC-1,
and KLE), five breast cancer cell lines (MCF7, MDA-MB-231,
MDA-MB-453, SKBR3, and T-47D), nine ovarian cancer cell lines
(ES-2, Caov-3, Caov-4, OV-90, OVCAR-3, SK-OV-3, SW 626,
TOV-112D, and UWB1.298), and three prostate cancer cell lines
(DU-145, LNCaP and PC-3) were obtained from the American Type
Culture Collection (ATCC, Manassas, VA) and were cultured
according to their guidelines. Two EC cell lines, Ishikawa H [19] and
the Hec50co subline [20] of the Hec50 cell line [21], were gifts from
Dr Erlio Gurpide of New York University and were grown in
Dulbecco's modified Eagle's medium supplemented with 10% FBS
and 1% penicillin-streptomycin (Life Technologies, Carlsbad, CA) as
we previously reported [20]. The Alva-31 cell line [22] was a gift from
Dr Thomas Griffith of the University of Iowa and was grown
in RPMI 1640 supplemented with 10% FBS and 1% penicillin-
streptomycin (Life Technologies). It has previously been reported that
the ECC-1 EC cell line originated from the 3-H-12 Ishikawa EC cell
subline [23]. Short tandem repeat genotyping was performed on all of
our cell lines and confirmed that our Ishikawa cells are from the
3-H-4 subline and that our ECC-1 cells are from the 3-H-12 subline.
While these cell lines share a common ancestor, they have distinct
genomic profiles and are used in this manuscript to demonstrate data
replication within different cellular backgrounds.
RNA Samples
A panel of RNA from 20 different human tissues was obtained
from Life Technologies, with each sample containing pooled RNA
from three individuals. To this panel, we added our own RNA sample
of pooled BE from three patients.TCGA Data Analysis
Clinical and miR-888 expression data for 450 uterine corpus EC
(UCEC) specimens were downloaded from TCGA data portal
(National Cancer Institute and National Human Genome Research
Institute, accessed 31 May 2013), and clinical characteristics are
summarized in Table S2. A full list of individual miR-888 expression
values in reads per kilobase per million (RPKM) and clinical
information by patient barcode are available in Table S3. MiR-888
expression data were also obtained for a panel of cancers using the
University of Iowa Institute for Clinical and Translation Science
Compass website (https://research.icts.uiowa.edu/compass/, accessed
28 February 2014). MiR-888 expression data were downloaded for
breast invasive carcinoma (BRCA, n = 380), colon adenocarcinoma
(COAD, n = 394), lung adenocarcinoma (LUAD, n = 407), ovarian
serous cystadenocarcinoma (OV, n = 476), pancreatic adenocarcino-
ma (PAAD, n = 43), prostate adenocarcinoma (PRAD, n = 187),
UCEC (n = 363), and uterine CS (UCS, n = 56), and individual
miR-888 expression values in RPKM for each cancer are provided
in Table S4.RNA and Protein Extraction from Cells and Tissues
Tissue samples were immersed in RNAlater ICE (Life Technol-
ogies) and incubated at −20°C for at least 16 hours before RNA
extraction. The mirVana miRNA Isolation Kit (Life Technologies)
was used to isolate total RNA from tissues according to the
manufacturer’s instructions. For cultured cells, RNA and protein
were isolated using the mirVana PARIS kit (Life Technologies).Quantitative Reverse Transcription–Polymerase Chain Reaction
Taqman primer/probe sets for hsa-miR-888 and RNU48 (Life
Technologies) were used to perform quantitative reverse transcription–
polymerase chain reaction (RT-PCR) on 200 ng of RNA using the
Taqman Reverse Transcription Kit followed by the 2× PCRMaster Mix
withNo AmpERASEUNG according to the manufacturer’s instructions
(Life Technologies). For PR quantification, primers for PR
(5′-ATGTGGCAGATCCCACAGGAGTTT-3′, 5′-ACTGGGTT
TGACTTCGTAGCCCTT-3′) and 18S (5′-AACTTTCGATGG
TAGTCGCCG-3′, 5′-CCTTGGATGTGGTAGCCGTTT-3′) were
designed using the PrimerQuest software from Integrated DNA
Technologies (Coralville, IA) and oligonucleotides were ordered from
Integrated DNATechnologies. RT was carried out using the SuperScript
III First Strand Synthesis System (Life Technologies) and PCR was
performed using the 2× Power SYBR Green PCR Master Mix (Life
Technologies) following the manufacturer’s protocol. Quantitative PCR
reactions were completed on the Applied Biosystems 7900HT Fast
Real-Time PCR System. Fold change was calculated using the
Comparative Ct Method (2−ΔΔCt) with RNU48 as the internal control
formiR-888 and 18S as the internal control for PR. For the normal tissues
(Figure 2A) and cell lines (Figure S1), data are reported as 2−ΔCt × 10,000
because there was no intuitive negative control group to use for fold
change comparisons.
miRNA In Situ Hybridization
In situ hybridization was performed using double-digoxigenin
(DIG) labeled 2′O-methyl locked nucleic acid (LNA)-ZEN probes
(Integrated DNA Technologies) complimentary to miR-888
(5 ′ -DIG-U/ZEN/GACUGACAGCUTUUUGAGU/ZEN/
A-DIG-3′) along with a scrambled negative control probe
(5 ′ -DIG-C/ZEN/GUAUUAUAGCCGAUUAACG/ZEN/
A-DIG-3′), where LNA modifications are underlined. Hematoxylin
and eosin (H&E) staining was performed using the Sakura Finetek
DRS 601 automatic slide stainer (Sakura Finetek USA Inc, Torrance,
CA). All in situ hybridization and H&E stains were performed on
adjacent serial sections of the same tissue sample. In situ hybridization
was performed following the protocol previously described by
McLoughlin et al. with the following modifications [24]. Tissue
sections were incubated with ZEN-LNA probes overnight at a
hybridization temperature of 55°C and a final concentration of 1 μM.
All samples were incubated with an alkaline phosphatase-conjugated
antibody to DIG (Roche, San Francisco, CA) at a dilution of 1:1000
overnight at 4°C. All images were taken using the same microscope
settings and differential interference contrast (Leica Microsystems,
Wetzlar, Germany). Each image background was then edited to white
using Adobe Photoshop (San Jose, CA).
miRNA In Situ Hybridization Intensity Scoring
Each seminiferous tubule was divided into three zones: A, B, and
C. Zone A represents the outer edge of the tubule in which the Sertoli
cells, spermatogonia, and primary spermatocytes are located, zone B
represents the region that contained spermatids and zone C represents
the lumen where mature sperm are located. For intensity scoring, 0 =
no blue staining, 1 = scant blue staining, 2 = moderate blue staining
and 3 = abundant blue staining. Scoring was blinded and performed
by pathologist Katherine Gibson-Corey, PhD, of the University of
Iowa. Each image contained one seminiferous tubule. Scoring was
performed for miR-888 staining in three rhesus macaque testis
samples with five images from each of three tissue sections.
Figure 2. MiR-888 is expressed in the testes during the early stages of spermatogenesis. (A) MiR-888 expression was measured by
quantitative RT-PCR in pooled RNA from 21 normal human tissues, and gene expression is reported as 2−ΔCt × 10,000. MiR-888 showed
high expression in the testes and a low-level expression in all other tissues examined. In situ hybridization was performed on serial tissue
sections of rhesus macaque testes using a probe complementary to miR-888 (C) or a scrambled probe (D) as a negative control. In B, an
H&E stain of a serial section of the same testis tissue sample is shown for comparison. In B and C, individual seminiferous tubules are
designated with an asterisk (*). (E) MiR-888 staining intensity was scored from 0 to 3 in three self-defined zones of the seminiferous
tubule: zone A= spermatogonia, primary spermatocytes, Sertoli cells; zone B= spermatids; zone C = spermatozoa. (F) MiR-888 staining
in each zone was analyzed for five images from three different biologic testis samples using a repeatedmeasures ANOVAmodel. Staining
intensity was significantly greater in zone A relative to zones B and C; error bars represent 95% confidence intervals.
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Cells were plated into phenol-red free medium with 10%
charcoal-stripped FBS (Life Technologies) to reduce the presence of
hormones. ECC-1 or Ishikawa cells were transfected with a plasmid
encoding miR-888 (Origene, Rockville, MD) or the empty vector
(EV) control (Origene) using Lipofectamine 2000 (Life Technolo-
gies) according to the manufacturer’s instructions. At 4 hours
post-transfection, cells were treated with 5 nM estradiol (Sigma, St.
Louis, MO) to induce PR expression. Cells were collected at 24 hours
post-transfection for RNA and protein isolation and analysis.Western Blot
A rabbit monoclonal antibody against PR isoform A/PR isoform B
(PRA/PRB, #3153; Cell Signaling Technology, Danvers, MA) was
combined with a rabbit monoclonal antibody against PRB (#3157;
Cell Signaling Technology) and both were diluted 1:1000. The
mouse monoclonal β-actin antibody (Sigma #A1978) was used as a
loading control for all Western blots at a dilution of 1:10,000. The
National Institutes of Health ImageJ program was used to perform
densitometry quantification and data were normalized to the
mock-transfected controls.
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An approximately 500-bp region surrounding each of the four
miR-888 binding sites in the PR 3′UTR was amplified from ECC-1
genomic DNA using the Platinum PCR SuperMix, High Fidelity
(Life Technologies; primer sequences in Table S5). PCR products
were purified using the PCR Purification Kit (Qiagen, Valencia, CA)
and subcloned into the pGEM-T Easy vector (Promega, Madison,
WI). Insert sequences were subsequently cloned into the
psiCHECK2 vector and transformed into TOP10 OneShot
competent E. coli (Life Technologies).
Dual Luciferase Assays
ECC-1 or Ishikawa cells were transfected with miR-888 or the EV
in combination with each individual psiCHECK2 luciferase vector.
Cells were collected at 24 hours post-transfection, and Firefly and
Renilla luciferase activities were measured using the Dual Luciferase
Assay System (Promega) according to the manufacturer’s protocol.Figure 3. MiR-888 is selectively expressed in aggressive endometria
were downloaded from TCGA for BRCA (n= 380), COAD (n= 394), LU
(n = 363), and UCS (n = 56). MiR-888 expression was significantly gr
(P b .05, Wilcoxon rank sum test). In A and B, undetectable expressi
invasion data were available for 396 UCEC tumor specimens and miR
regression splines were used to estimate the nonlinear relations
association was significant, P = .03). (C) miR-888 expression was m
primary tumors that included 18 EAs, 9 SAs, and 9 CSs. MiR-888
overexpressed in EA (P b .01), 3-fold overexpressed in SA (P = .20
confidence intervals.Renilla luciferase activity was divided by Firefly luciferase activity
and normalized to the EV control.
Statistical Analysis
For the in situ hybridization semiquantification, a repeated
measures analysis of variance (ANOVA) model was used to analyze
the data, because multiple images of each sample were scored. Due to
the highly skewed nature of miR-888 expression in TCGA samples,
figures are expressed on the square-root scale and observations below
the limit of detection are jittered slightly for display purposes. For
testing miR-888 expression levels across cancer types from TCGA
data, Wilcoxon rank sum tests were used. Penalized regression splines
were used for the nonparametric regression model presented in
Figure 3B [25]. PCR data involving miR-888 and PR expression,
Western blot data, and luciferase assays were all analyzed using
ANOVA models. Linear regression was used to assess the significance
of the correlation between miR-888 and PR mRNA expression in ECl tumors. (A) MiR-888 deep sequencing expression data in RPKM
AD (n= 407), OV (n= 476), PAAD (n= 43), PRAD (n= 187), UCEC
eater in UCEC and UCS compared to all other cancers investigated
on levels are jittered slightly to avoid overplotting at 0. (B) Percent
-888 RPKM correlated with increasing percent invasion. Penalized
hip between miR-888 expression and percent invasion (overall
easured by quantitative RT-PCR in a group of nine BE and 35 EC
was 9-fold overexpressed in EC as a whole (P b .01), 11-fold
), and 22-fold overexpressed in CS (P b .01); bars represent 95%
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triplicate on three separate occasions to produce nine individual
replicates per experimental condition for statistical analysis.
Results
MiR-888 is Selectively Expressed in the Testes During the Early
Stages of Spermatogenesis
Previously reported deep sequencing data have shown that miR-888
expression is restricted to the testes [6]. To confirm these analyses, we
obtained pooled RNA samples from 21 different normal adult human
tissues and quantified miR-888 expression through quantitative
RT-PCR (Figure 2A). As expected, miR-888 demonstrated excep-
tionally high expression in the testes and minimal or no detectable
expression in all other tissues investigated (Figure 2A). The majority of
tissues had very low miR-888 expression [raw cycle threshold (Ct)
value of 30–40]. The kidney, prostate, and thymus were the only other
tissues that had Ct values less than 30 (Ct ≈ 28–30), but their
expression was minimal compared to that observed in the testes (raw
Ct = 22). To determine the distribution of miR-888 expression within
the testes, we performed miRNA in situ hybridizations on rhesus
macaque testis tissue from three individual monkeys. H&E staining
was performed on a serial section for tissue structure comparison
(Figure 2B). The in situ hybridizations were performed using a probe
complimentary to miR-888 (Figure 2C ) or a scrambled probe
(Figure 2D) as a negative control. miR-888 expression consistently
localized to the outer edge of the seminiferous tubule (Figure 2C ).
Spermatogenesis occurs within the seminiferous tubules of the
testes. As the germ cells mature, they move towards the center of the
tubule. To assess miR-888 expression during sperm maturation, the
seminiferous tubule was divided into three different zones and scored
for miR-888 intensity by a trained pathologist blinded to sample
identity (Figure 2E). Zone A encompasses the outer edge of the
seminiferous tubule where spermatogonia, primary spermatocytes,
and Sertoli cells are located. Zone B represents the region that
typically contains the maturing spermatids, and zone C represents the
lumen of the testes where mature spermatozoa are located. Using a
staining intensity range of 0–3, zone A consistently showed the
highest level of staining (Figure 2F). Thus, miR-888 expression
predominantly localized to the early stages of spermatogenesis within
the seminiferous tubule of the testes.
MiR-888 Is Selectively Overexpressed in Endometrial Tumors
To investigate miR-888 expression in cancer, we used TCGA
database and obtained miR-888 expression for a panel of carcinomas
that included BRCA (n = 380), COAD (n = 394), LUAD (n = 407),
OV (n = 476), PAAD (n = 43), PRAD (n = 187), UCEC (n = 363), and
UCS (n = 56; Table S4). MiR-888 expression was significantly elevated
in UCEC and UCS compared to all other cancers (P b .05 for all
pairwise comparisons involving UCEC and UCS; the two types were
not, however, significantly different from each other). DetectableTable 1. MiR-888 Expression by Tumor Grade
Grade Percentage of Samples with Nonzero miR-888 Expression
G1 17%
G2 24%
G3 36% *
* P = .001.expression of miR-888 was only observed in a minority of specimens
from other cancers (Figure 3A). We also investigated miR-888
expression across a panel of cancer cell lines originating from breast,
endometrial, ovarian, and prostate tumors and found that miR-888
levels were highest in EC cell lines (Figure S1), albeit low in comparison
to testes (Figure 2A) and individual miR-888 expressing endometrial
tumors (Figure S2). The cell line data support TCGA results in that
miR-888 expression was highest in EC. MiR-888 expression in
endometrial tumors from TCGA data was heavily skewed, with 65% of
samples having undetectable expression of miR-888 (Figure 3A and
Table S2). Such a specific expression pattern is characteristic of CT
antigens, which are not endogenously expressed in the tumor tissue of
origin [3]. UCEC tumors that had positive expression of miR-888 were
substantially more likely to be grade 3 tumors than UCEC tumors with
undetectable miR-888 levels (Table 1, P = .001). Furthermore,
miR-888 expression in UCEC tumors showed a positive association
with percent invasion of the tumor (Figure 3B). Therefore, miR-888
expression in endometrial tumors correlates with a more aggressive
tumor phenotype and has an expression pattern in cancer similar to
other representative CT antigens.
To validate TCGA miR-888 expression data, we obtained RNA
from 9 benign endometrial tissues and 35 endometrial tumor
specimens that included 18EAs, 9 SAs, and 8CSs (Table S1).MiR-888
was nine-fold overexpressed in endometrial tumor specimens compared
to BE with a P value b .01 (Figures 3C and S2). Within endometrial
tumor subtypes, miR-888 was significantly overexpressed in EA
(11-fold, P b .01) and most predominantly overexpressed in CS
(22-fold, P b .01). Endometrial CS is a rare but very aggressive form of
EC that has a very poor prognosis and limited treatment options [26].
In contrast, EA often presents at an early stage and grade and can be
treated by surgical removal alone [27]. Thus, these data suggest that
miR-888 is associated with an aggressive tumor phenotype.
To determine what cell types expressed miR-888 in endometrial
tumors, we performed miRNA in situ hybridization on EA and CS
samples (EA38 and CS114; Table S1) that had particularly high
expression of miR-888. H&E staining for the EA and CS samples was
performed on adjacent tissue sections as a reference (Figure 4, A and B).
In EA, miR-888 expression localized to the cancerous glandular
epithelium (Figure 4C), with minimal staining in the surrounding
stroma and the absence of staining observed for the scrambled negative
control probe (Figure 4D). CS is unique in that it contains both
carcinomatous and sarcomatous components within a single tumor. It is
hypothesized that the cancer was originally an endometrial carcinoma
that dedifferentiated to form sarcoma-like cells [28]. MiRNA in situ
hybridization of an endometrial CS revealed that miR-888 expression
remained in the carcinomatous portion of the tumor (Figure 4, E
and F ). Interestingly, the carcinomatous portion of the tumor is
typically the cell type functionally involved in tumor invasion and
metastasis [28]. These data demonstrate that miR-888 expression is
restricted to the cancerous glandular epithelium of endometrial tumors
and points to the role of miR-888 in cancer cell signaling pathways.
PR Expression in EC
In the same subset of tumor tissues used for miR-888
quantification, we also quantified PR mRNA expression (7 benign
samples of endometrium, 12 EAs, 7 SAs, and 7 CSs; Table S1; samples
not used did not have enough remaining RNA). As has been reported
previously [16,29], we observed a loss of PR expression in endometrial
tumors compared to BE (Figures 5A and S2). PR expression was
Figure 4.MiR-888 expression localizes to the cancerous epithelium. Serial tissue sections were cut from the EA38 EA tissue (A, C, and D)
and the CS114 CS tissue (B, E, and F; see Table S1 for tissue sample details). These tissue samples were chosen for their high expression
of miR-888 demonstrated by quantitative RT-PCR. For comparison, H&E-stained sections are shown in A and B. MiRNA in situ
hybridization was performed using a probe complimentary to miR-888 (C and E) or a scrambled negative control probe (D and F). For C,
the border between the cancerous epithelium and adjacent normal stromal is designated by a dotted line. For B and E, the border
between the carcinomatous and sarcomatous elements is designated by a dotted line. In A and C, endometrial glands are designated by
an asterisk (*).
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relative to BE (P b .0001). In CS, PR expression was essentially absent
(1000-fold decreased, P b .0001; Figure 5A). Linear regression
demonstrated a statistically significant negative correlation between
miR-888 and PR mRNA expression (R = −0.579, P value b .001;
Figure 5B). In particular, this implies that a five-fold increase in
miR-888 concentration is associated with a three-fold decrease in PR
concentration (95% confidence interval: 1.7 to 5.3).
MiR-888 Inhibits the PR in EC
Given the significant association between miR-888 and PR mRNA
levels, we next analyzed the 3′UTR of PR for potential binding sites
for miR-888 using TargetScanHuman 6.2 (www.targetscan.org).
Similar to other steroid hormone receptors, PR has a very long 3′UTR
(≈10 kilobases) with several AU-rich elements (AREs; Figure 6A,
stars), suggesting a very complex post-transcriptional regulatorymechanism. Intriguingly, the PR 3′UTR contained four binding
sites for miR-888 in its 3′UTR (Figure 6A, triangles), with the first
three sites having 7mer-m8 complementarity and the last site having
8mer complementarity (Figure 6F ). To investigate the role of
miR-888 regulation of PR, we chose to use the ECC-1 and Ishikawa
EC cells because they had a low level of miR-888 expression (Figure S1)
and are positive for PR expression [20,30]. The ECC-1 and Ishikawa
EC cell lines were transfected with a plasmid containing the miR-888
gene (miR-888) or an EV as a negative control, and miR-888
expression was confirmed by quantitative RT-PCR (Figure S3).
Mock transfections were performed as a negative control and were
used for data normalization. At 4 hours post-transfection, cells were
treated with 5 nM estradiol to induce PR expression. Protein was
isolated at 24 hours post-transfection, and Western blot analysis was
performed for PR isoforms PRA and PRB. Only PRB was
predominantly expressed in ECC-1 and Ishikawa cells, and
Figure 5. PR mRNA expression negatively correlates with miR-888 expression. (A) PR mRNA was measured by quantitative RT-PCR in 7
BEs, 12 EAs, 7 SAs and 7 CSs. PRmRNAwas significantly decreased in all three types of EC; bars represent 95% confidence intervals and
P values are displayed to the right. (B) A linear regression was performed using the PR mRNA and miR-888 ΔCt values and a significant
negative correlation was observed with a correlation coefficient of R = −0.58 and P b .001. Cancer subtype is indicated by different
colored data points.
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level in both cell lines (Figure 6, B and C ). Western blots were
quantified by densitometry using ImageJ software, and a significant
decrease in PR protein was observed with miR-888 transfection, but
not EV transfection, relative to the mock-transfected controls in the
ECC-1 (Figure 6D) and Ishikawa (Figure 6E ) cell lines.
To validate PR as a direct target of miR-888 regulation, we cloned
500-bp regions surrounding each PR 3′UTR miR-888 binding site
(Figure 6F ) into the psiCHECK2 vector downstream of Renilla
luciferase. ECC-1 and Ishikawa cells were transfected with the
miR-888 plasmid in combination with each PR-psiCHECK2 vector
(sites PR1-PR4; Figure 6F ), and luciferase activity was measured
24 hours post-transfection. Renilla luciferase activity was normalized
to Firefly luciferase activity and data are reported relative to the EV
transfection (Figures 6, G and H ). Expression of miR-888 caused a
significant reduction in luciferase activity of approximately 10% to
20% for all four binding sites in both cell lines (Figures 6, G and H ).
Therefore, these data support that PR is a direct target of miR-888
regulation in EC cells.
Discussion
Here, we describe for the first time a miRNA, miR-888, that
embodies the cardinal characteristics of a CT antigen. This is the first
noncoding RNA to meet these criteria. Though CT antigens were
historically identified through their ability to elicit an immune
response when expressed in tumors, the term CT antigen has evolved
to include a broader range of characteristics. There are more than
200 CT antigens currently classified in the CT antigen database
(http://www.cta.lncc.br), many of which have yet to be investigated
for their immunogenic potential [3]. Further, several CT antigens
that were originally described as immunogenic have more recently
been shown to elicit only a minimal immune response in vivo[3].
Therefore, even though the term antigen signifies an immunogenic
molecule, not all CT antigens display this trait. A more fundamental
characteristic of CT antigens is their highly restricted expression
pattern in testes and cancer. Therefore, we suggest that noncoding
RNAs displaying this expression pattern can be appropriately
categorized as CT antigens.In 2010, Li et al. reported the evolution of a primate-specific
X-linked miRNA gene family spanning a 33-kilobase region at
Xq27.3 [5]. The miR-888 gene family is located in a 3-kilobase
cluster within this region and includes the miRNAs miR-888,
miR-890, miR-891a, miR-891b, miR-892a, and miR-892b [5].
Rapid evolution through gene duplication events resulted in the
emergence of the miR-888 family members in primates [5]. Ohno’s
law predicts that X-linked genes are more highly conserved across
placental mammals than autosomal genes due to X chromosome
inactivation and gene dosage effects [31]. However, CT-X antigen
genes are often exceptions to this rule [4,32]. It has been hypothesized
that recessive genes that are selectively beneficial to males become
fixed more rapidly on the X chromosome than on the autosomes [33].
This makes the X chromosome a hotspot for CT-X antigens, while
the remaining genes on the X-chromosome are highly conserved and
follow Ohno’s law [33]. MiR-888 follows the specific evolutionary
pattern of CT-X antigens with its recent evolution on the
X-chromosome and restricted expression in testis [5]. In addition,
miR-888 has predicted targets that are known to be involved in sperm
cell production and regulation within the testes [5,6]. We extend this
literature by identifying miR-888 expression in cells during the early
stages of spermatogenesis within the seminiferous tubules of the
testes. This information supports the evolution of the miR-888 gene
locus in primates as a CT-X antigen that likely plays a role in testis
cell biology.
Landgraf et al. first discovered the miR-888 gene family through
small RNA library sequencing and reported highly specific expression
of the miRNA family in the epididymis of the testes [6]. Belleannee
et al. performed microarrays to investigate miRNA expression across
different regions of the epididymis [34]. All members of the miR-888
family, except for miR-888, were found to be differentially expressed
throughout the epididymis [34]. Furthermore, miR-888 expression
was very low in the epididymis relative to its other family members,
suggesting that it might not play a prominent role in this tissue [34].
Our data show that miR-888 expression is highly specific to the testes,
with a low level of expression in the kidney, prostate, thymus, and
trachea. MiR-888 has previously been detected in regions outside the
testes but not in normal tissue under endogenous conditions [35,36].
Figure 6.MiR-888 directly targets the PR. (A) PR contains four miR-888 binding sites in its 3′UTR (PR1-PR4, triangles) along with several
AREs (stars). Expression of miR-888 was capable of decreasing PR expression at the protein level in both ECC-1 (B) and Ishikawa (C) EC
cell lines. Western blots were quantified by densitometry, and PR protein was significantly decreased bymiR-888, but not EV transfection,
relative to the mock-transfected controls (D: ECC-1, E: Ishikawa). In F, the individual miR-888 binding sites in the PR 3′UTR are aligned
with the miR-888 miRNA nucleotide sequence and nucleotide base interactions are denoted with vertical lines. ECC-1 (G) or Ishikawa (H)
cells were transfected with luciferase reporters containing each PR 3′UTR miR-888 binding site (PR1-PR4) downstream of Renilla
luciferase in combination with miR-888 or the EV control. MiR-888 expression resulted in a significant decrease in luciferase activity
compared to the EV control for all four miR-888 binding sites (G: ECC-1, H: Ishikawa). For D, E, G, and H, statistical significance was
determined using ANOVA models and error bars represent 95% confidence intervals. P values are listed above each bar graph.
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oocytes, yet miR-888* has a different miRNA seed sequence [37].
Therefore, we conclude that miR-888 expression is highly enriched in
the human testes. It is also important to note that quantitative RT-PCR
is a very sensitive technique and has demonstrated expression of many
CT antigens in tissues in addition to testes, albeit at much lower levels
[3]. Therefore, miR-888 expression across normal human tissues is
consistent with observations of other CT antigens.
Heterogeneous expression of miR-888 across various cancer types
was observed wherein miR-888 was only expressed in a small subset of
tumors. This expression pattern is characteristic of CT antigens,
which are not expressed in the tumor tissue of origin and are only
expressed in a portion of tumors [1]. In a panel of eight different typesof tumors, miR-888 was most predominantly expressed in EC. This is
particularly relevant in that similar to the testes, the endometrium is a
tissue governed by extensive hormonal regulation. Association of
miR-888 expression with endometrial tumors of high grade and
increased invasion implies that miR-888 expression indicates a more
advanced form of EC. Furthermore, miR-888 was most highly
expressed in the very rare and aggressive endometrial CS, which has
often metastasized at the time of diagnosis and has a poor five-year
survival rate of only 20% to 35% [26]. Expression of other CT
antigens has also been correlated with aggressive tumors [38]. In EC,
CT antigens MAGEC1, MAGEA3, and MAGEA4 expression
correlated with high-grade tumors [39], and MAGEA4 and
NY-ESO were most predominantly expressed in endometrial CSs
94 miR-888: A Novel Cancer-Testis Antigen Hovey et al. Translational Oncology Vol. 8, No. 2, 2015[40]. Thus, miR-888 expression in endometrial tumors is consistent
with the characteristic expression patterns observed for CT antigens.
One of the most important findings reported herein is the
identification of PR as a direct target of miR-888. Throughout
evolution, 3′UTR length has expanded, with steroid hormone
receptors demonstrating the most extensive elongation [41]. The PR
3′UTR underwent recent expansion in primates to approximately 10
kilobases in length, generating new miRNA binding sites for
evolutionarily novel miRNAs such as miR-888 [42]. The PR 3′
UTR also contains binding sites for many other miRNAs, such as the
recently validated miR-96 [43] and miR-126-3p [44], as well as the
predicted regulators miR-181 and miR-26a [45]. The PR 3′UTR
contains many AREs as well, rendering the mRNA highly unstable
[46]. Therefore, the post-transcriptional regulation of PR is
multifactorial and complex. The miR-888–dependent decrease in
PR protein expression and 3′UTR luciferase reporter activity that we
report here was relatively modest. Due to the AU-rich nature of
miR-888, this is not surprising and is consistent with previous
reports. For example, Garcia et al. report that AU-rich miRNA seeds
have lower seed pairing stability and higher target abundance,
rendering them less proficient [47]. In addition, a modest reduction
in target protein levels by miRNAs has been reported by others
previously [48–50]. Baek et al. performed protein arrays after
knockout of miR-223 and found that a large number of targets were
only reduced by about 30% [51]. The authors hypothesized that
many miRNAs function through a fine-tuning mechanism rather
than causing a dramatic change in protein translation of target
mRNAs [51]. We suggest that miR-888 is but one of several factors
using the long PR 3′UTR to regulate mRNA stability and protein
translation. These different regulators likely work together through
cross-talk mechanisms to cause a more pronounced and cumulative
effect on PR protein expression than any one could have alone.
The importance of PR in the testes has recently been investigated.
Shah et al. reported that PR expression is low during the early stages of
spermatogenesis and highest during late stages IV and V [52]. Here,
we show an opposite staining pattern for miR-888 in Rhesus testes,
with high expression in the early stages of spermatogenesis and the
absence of expression in the later stages. Therefore, we suggest that
miR-888 might function to keep PR low during the early stages of
spermatogenesis, followed by a loss of miR-888 expression during the
late stages of spermatogenesis, permitting PR to induce germ cell
differentiation. Consistent with this hypothesis, Abid et al. reported
that PR expression was lost in men with infertility due to
nonobstructive azoospermia, in which germ cells fail to mature into
spermatozoa [53]. In addition, miR-888 appeared in a screen for
miRNAs differentially expressed in sperm from infertile males with
oligozoospermia and asthenozoospermia [54]. MiR-888 was over-
expressed in both types of male infertility, despite the fact that the
P values did not reach statistical significance in this relatively small
sample size [54]. Nevertheless, the preponderance of the literature
indicates that tight regulation of PR signaling is essential for proper
germ cell maturation, thus establishing a potential role of miR-888 in
male fertility.
Conclusions
We propose that miR-888 should be considered the first miRNA CT
antigen. MiR-888 recently evolved in primates on the X chromosome
and is expressed specifically during the early stages of spermatogenesiswithin the testes. MiR-888 is also overexpressed in cancer, specifically
in endometrial tumors. Moreover, expression was only observed in a
subset of endometrial tumors and was associated with high-grade and
enhanced tumor invasion into the myometrium. In EC cells, we
confirm PR as a direct target of miR-888 regulation. With PR well
described as a tumor suppressor of the endometrium, miR-888 is a
potential oncogene in EC. MiR-888 likely works in combination
with other miRNAs and factors to post-transcriptionally regulate PR.
The role of miR-888 in the testes is not yet fully defined, but
regulation of PR by miR-888 in the spermatogenic cells of the testes is
an intriguing hypothesis for future research.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2015.02.001.
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